Newsfiscal.ai
Imunon Presents New Translational Data for IMNN-001 at SITC 2026
· Published
Article summary
Imunon, Inc. presented new translational data from its Phase 2 OVATION 2 study of IMNN-001 for advanced ovarian cancer at the SITC 2026 annual meeting.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…